Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

In a recent study published in the Respiratory Research journal, researchers in Hong Kong assessed the deterioration of asthma control in patients recovering from mild to moderate coronavirus disease ...

Please provide your email address to receive an email when new articles are posted on . The treatment group had reductions in FeNO 1 week after a single dose. Reductions were significant compared with ...

Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed. After receiving ...

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) on Tuesday shared interim data from the Phase 1b trial of zumilokibart (APG777) in patients with mild-to-moderate asthma. The data covers 19 adult patients ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the phase ...

With the inclusion of the BATURA study, Airsupra has now demonstrated its effectiveness in reducing the risk of severe exacerbations across all severity levels of asthma vs albuterol. The Food and ...

New research from National Jewish Health suggests that long-acting beta-agonists (LABAs), commonly used in combination asthma ...

SAN DIEGO — Asthma afflicts 8.1% of school-age children in the United States and is a leading cause of missed school and work. Having stock inhalers available at schools prevents asthma-related ...